Julie Anne Smith
President and Chief Executive Officer
Prior to joining E-Scape, Ms. Smith was president and chief executive officer of Nuredis, a biotechnology company focused on neurodegenerative diseases caused by long nucleotide repeats such as Huntington's disease. She previously served as president and CEO of Raptor Pharmaceuticals, which developed and commercialized therapies for the orphan disease nephropathic cystinosis and chronic pulmonary infections in cystic fibrosis before its acquisition by Horizon Pharmaceuticals. Ms. Smith also served as chief commercial officer of Enobia Pharmaceuticals until it was acquired by Alexion in 2012.
Earlier in her career, she held roles at Jazz Pharmaceuticals, Genzyme, Novazyme and Bristol-Myers Squibb. Ms. Smith serves as a director on the boards of Exelixis, Inc. (EXEL) and Audentes Therapeutics (BOLD). Ms. Smith obtained her Bachelor of Science in biology from Cornell University.